Fair Value Calculator Fair Value Calculator
EN DE

002800 (002800) Fair Value & Analysis

Healthcare · Market cap 70.2B KRW

0 002800 002800 · KQ
Price4,260 KRW
Fair Value8,575 KRW
Upside+101.3%
Quality53/100
Watch 002800 for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range 6,085 KRW – 10,719 KRW

Fair value as of: Jun 25, 2026

From 24 valuation models · updated 7 days ago

Share price −8.9% over the past month.

Price vs Fair Value (12 months)

6,389 KRW 3,992 KRW Fair Value 8,575 KRW Jun 2025 Jul 2026

12‑month range 3,992 KRW – 6,389 KRW · fair‑value band 6,085 KRW – 10,719 KRW · the 4,260 KRW price screens below the 8,575 KRW fair value. As of Jun 25, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

002800 (002800) currently trades at 4,260 KRW, while our model-based Fair Value estimate is 8,575 KRW — implying the stock looks roughly 101.3% undervalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 002800 generated revenue of 119B KRW at a net margin of 9.4%. Revenue grew 19.2% year over year. It earns a return on equity of 15.6%. Net debt stands at 39.6B KRW. Fundamentals as of Jun 25, 2026

Key figures & financial health

Revenue (TTM) 119B KRW
Revenue growth (YoY) +19.2%
Net margin 9.4%
Return on equity 15.6%
Free cash flow 7.0B KRW FY2025
Operating margin 10.5%
More key figures
Dividend yield 1.8%
EPS growth (YoY) +186%
Net debt 39.6B KRW FY2025

Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

002800 reported revenue of 114B KRW in FY2025 versus 74.0B KRW in FY2021, a compound +11.4%/yr. Reported net income was 9.3B KRW in FY2025.

Revenue +11.4%/yr
FY21 74.0B KRW
FY22 91.9B KRW
FY23 103B KRW
FY24 106B KRW
FY25 114B KRW
Net income
FY21 −1.5B KRW
FY22 4.4B KRW
FY23 4.7B KRW
FY24 4.9B KRW
FY25 9.3B KRW

Is 002800 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).

Stock Price Fair Value vs Fair Value
1276 1276 HK$57.85 HK$29.84 -48%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.08 ¥26.59 -44%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,786 ₹991.46 -44%
Zoetis Inc Z1TS34 R$25.93 R$19.70 -24%
Hansoh Pharmaceutical Group 3692 HK$29.30 HK$23.90 -18%
Divi's Laboratories Limited DIVISLAB ₹6,639 ₹1,281 -81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 002800 (002800) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 8,575 KRW versus a price of 4,260 KRW — about +101% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 002800?
Our model-based fair value for 002800 is 8,575 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 4,260 KRW.
What is the quality score of 002800?
002800 has a Quality Score of 53/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 002800 (002800)?
002800 reported trailing-twelve-month revenue of about 119B KRW (latest available figure, as of Jun 25, 2026).
What is the net profit margin of 002800?
The net profit margin of 002800 is about 9.4%, meaning it keeps roughly 9.4% of revenue as net income. Based on the latest reported figures.
Does 002800 pay a dividend?
002800 currently shows a dividend yield of about 1.76% relative to its recent price (as of Jun 25, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.